Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC

Prostate Cancer and Prostatic Diseases, Published online: 30 August 2019; doi:10.1038/s41391-019-0172-zTherapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research

Related Links:

ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Beyond simply being discontent about the high cost of health care in the nation, consumers remain in the dark over what that cost may be – even for a standard treatment for prostate cancer, according to a study out of UNC-Chapel Hill.
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
(Wiley) Among men with prostate cancer who received care from the Veterans Affairs (VA) Health System, an equal-access health care system, African-American men did not have more advanced disease at the time of diagnosis or die earlier than white men, unlike trends seen in the greater US population of patients with prostate cancer. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
ConclusionOur results suggest improved detection of PCa with similar PPV and confidence scores when higher TE values are utilized for T2-weighted image acquisition.
Source: Academic Radiology - Category: Radiology Source Type: research
Baseline prostate-specific antigen (PSA) levels in midlife are associated with the subsequent risk of clinically significant prostate cancer, according to a secondary analysis of a large clinical trial.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
ConclusionsAge, Gleason score, and PSA at diagnosis of mCRPC are independently associated with overall survival in patients with mCRPC. The efficacy and toxicity outcomes in this patient cohort treated in radiation oncology departments in Spain are consistent with previous reports.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, the present study identified 20 aberrantly methylated‑differentially expressed genes in PCa by combining bioinformatics analyses of gene expression and gene methylation microarrays, and concurrently, the survival of these genes was analyzed. Notably, methylation is a reversible biological process, which makes it of great biological significance for the diagnosis and treatment of prostate cancer using bioinformatics technology to determine abnormal methylation gene markers. The present study provided novel therapeutic targets for the treatment of PCa. PMID: 31974616 [PubMed - in process]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
Source: BMJ Comments - Category: General Medicine Source Type: forums
In this study, we found that the mutation, copy number alteration, and methylation status of PRKAR2B gene have no correlation with its expression level in PCa. Then, we identified two microRNAs (miR-200b-3p and miR-200c-3p) to be critical regulators of PRKAR2B expression in PCa. Notably, miR-200b-3p and miR-200c-3p expression were significantly downregulated in metastatic CRPC and negatively correlated with the expression level of PRKAR2B in PCa tissues. Moreover, we characterized X-Box Binding Protein 1 (XBP1) as a key transcription factor responsible for PRKAR2B expression in PCa. Importantly, miR-200b-3p/200c-3p or XBP1...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Urology & Nephrology